About Tandem Diabetes
Tandem Diabetes is a company based in San Diego (United States) founded in 2008. Tandem Diabetes has raised $100.73 million across 6 funding rounds from investors including CRG. The company has 2,650 employees as of December 31, 2024. Tandem Diabetes has completed 4 acquisitions, including Advanced Microfluidics, Amf Medica and Capillary Biomedical. Tandem Diabetes operates in a competitive market with competitors including Kaleido, Modular Medical, LenoMed, Asante Solutions and Sooil Development, among others.
- Headquarter San Diego, United States
- Employees 2650 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Tandem Diabetes Care, Inc.
-
Annual Revenue
$940.2 M (USD)25.74as on Dec 31, 2024
-
Net Profit
-$96.03 M (USD)56.86as on Dec 31, 2024
-
EBITDA
-$82.52 M (USD)40.53as on Dec 31, 2024
-
Total Equity Funding
$100.73 M (USD)
in 6 rounds
-
Latest Funding Round
$287.5 M (USD), Post-IPO
May 15, 2020
- Investors
-
Employee Count
2650
as on Dec 31, 2024
-
Investments & Acquisitions
Advanced Microfluidics
& 3 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Tandem Diabetes
Tandem Diabetes is a publicly listed company on the NASDAQ with ticker symbol TNDM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Tandem Diabetes
Unlock access to complete
Unlock access to complete
Software Development Team
79 people
Sales and Marketing
32 people
Leadership Team
31 people
Finance and Accounting
14 people
Human Resources and Administration
14 people
Operations Team
13 people
Senior Team
13 people
Product Management Team
11 people
Unlock access to complete
Funding Insights of Tandem Diabetes
Tandem Diabetes has successfully raised a total of $100.73M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $287.5 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Tandem Diabetes
Tandem Diabetes has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include CRG.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
CRG is recognized as a premier healthcare investment partner.
|
Locked | Locked | Locked |
Investor details for Tandem Diabetes
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Tandem Diabetes
Tandem Diabetes has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Advanced Microfluidics, Amf Medica and Capillary Biomedical.
Investment portfolio details for Tandem Diabetes
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Smart solutions for blood glucose monitoring are provided by Sugarmate.
|
Locked | Locked | 2016 | Locked | |
|
Syringe pumps, electric rotary valves, and microfluidics are manufactured.
|
Locked | Locked | 2014 | Locked | |
|
Minimally invasive implants for continuous glucose monitoring are provided.
|
Locked | Locked | 2014 | Locked |
Complete acquisition details for Tandem Diabetes
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Tandem Diabetes
Detailed financials for Tandem Diabetes
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Tandem Diabetes Comparisons
Peer comparison for Tandem Diabetes
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Tandem Diabetes
Tandem Diabetes operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kaleido, Modular Medical, LenoMed, Asante Solutions and Sooil Development, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Insulin pumps and monitoring software for diabetes are developed.
|
|
| Locked | Locked | Locked |
Insulin pumps are developed for continuous delivery to diabetic patients.
|
|
| Locked | Locked | Locked |
Developer of closed loop insulin delivery devices
|
|
| Locked | Locked | Locked |
Insulin pump systems are developed and customized by Asante Solutions.
|
|
| Locked | Locked | Locked |
Develops insulin pumps and apps for diabetes care and blood sugar monitoring.
|
Detailed competitors of Tandem Diabetes
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Tandem Diabetes
Complete news archive for Tandem Diabetes
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Tandem Diabetes
Tandem Diabetes was founded in 2008 and raised its 1st funding round 2 years after it was founded.
Tandem Diabetes is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Tandem Diabetes is a funded company, having raised a total of $100.73M across 6 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Tandem Diabetes is 2,650.
Annual revenue of Tandem Diabetes is $940.2M as on Dec 31, 2024.
Tandem Diabetes is a developer of devices for continuous glucose monitoring and manual insulin delivery. It develops insulin pumps other products and services that bring innovation, convenience style to diabetes management. The first product, the t: slim Insulin Pump, features a sleek, modern design, intuitive touch-screen interface, and a rechargeable lithium-polymer battery. The company claims that this makes them closer to producing a fully automated closed-loop automated insulin delivery device that will not require human intervention to release insulin.
Tandem Diabetes's top competitors include Kaleido, Modular Medical and LenoMed.
Yes, Tandem Diabetes is publicly traded on NASDAQ under the ticker symbol TNDM.
Tandem Diabetes has made 4 acquisitions, including Advanced Microfluidics, Amf Medica, and Capillary Biomedical.
Tandem Diabetes has 1 investor. Key investors include CRG.
The ticker symbol of Tandem Diabetes is TNDM on NASDAQ.